Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-02-2022 | Stem Cell Transplantion | Brief Report

Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro

Authors: Jessica Fernandes Ramos, Gleice Leite, Roberta Cristina Ruedas Martins, Camila Rizek, Sabri Saeed Al Sanabani, Flavia Rossi, Thais Guimarães, Anna Sara Levin, Vanderson Rocha, Silvia Figueiredo Costa

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2022

Abstract

Bloodstream infection (BSI) caused by carbapenem-resistant P. aeruginosa (CRPA) has high mortality in hematopoietic stem cell transplant (HSCT) recipients. We performed MIC, checkerboard, time-kill assay, PFGE, PCR, and whole genome sequence and described the clinical outcome through Epi Info comparing the antimicrobial combination in vitro. Mortality was higher in BSI caused by CRPA carrying the lasB virulence gene. The isolates were 97% resistant to meropenem displaying synergistic effect to 57% in combination with colistin. Seventy-three percent of the isolates harbored bla_SPM-1 and Tn4371 and belonged to ST277. The synergistic effect in vitro with meropenem with colistin appeared to be a better therapeutic option.

Available only for authorised users

Gonçalves IR, Dantas RCC, Ferreira ML, Batistão DWF, Gontijo-Filho PP, Ribas RM (2017) Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation. Braz J Microbiol 48(2):211–217CrossRef

Andria N, Henig O, Kotler O, Domchenko A, Oren I, Zuckerman T, Ofran Y, Fraser D, Paul M (2015) Mortality burden related to infection with carbapenem-resistant gram-negative bacteria among hematological cancer patients: a retrospective cohort study. J Antimicrob Chemother 70:3146–3153CrossRef

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93CrossRef

Peña C, Cabot G, Gómez-Zorrilla S, Zamorano L, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez-López F, Tubau F, Martínez-Martínez L, Oliver A (2015) Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 60:539–548CrossRef

El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H (2012) Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 40:1157–1163CrossRef

Veesenmeyer JL, Hauser AR, Lisboa T, Rello J (2009) Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 37:1777–1786CrossRef

El Zowalaty ME, Al Thani AA, Webster TJ, El Zowalaty AE, Schweizer HP, Nasrallah GK, Marei HE, Ashour HM (2015) Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiol 10(10):1683–1706CrossRef

Peña C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez F, Tubau F, Oliver A, Martínez-Martínez L (2013) Effect of adequate single-drug versus combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections. A post hoc analysis of a prospective cohort. Clin Infect Dis 57:208–16CrossRef

Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M (2013) Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57(10):5104–11CrossRef

10.

Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care– associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332CrossRef

11.

Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, Ha Song JH (2009) Scoring Systems for prediction of mortality in patients with intensive care unit acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and chronic health evaluation II scoring systems. Shock 31(2):146–50CrossRef

12.

Clinical and Laboratory Standard Institute (2014) Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. CLSI document M100 S19. CLSI, Wayne

13.

Eliopoulos GM, Moellering RC (1996) In: Antimicrobial combinations. Antibiotic in Laboratory Medicine (4th edn). Lorian V, Williams and Wilkins, Baltimore, p 330–96

14.

Petersen PJ, Labthavikul P, Jones CH, Bradford PA (2006) In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by checkerboard and time-kill kinetic analysis. J Antimicrob Chemother 57(3):573–576CrossRef

15.

Pillai SK, Moellering RC, Eliopoulos GM (2005) In: Lorian V (ed) Antimicrobial combinations. Antibiotics in laboratory medicine, 5th edn. Lippincott Williams and Wilkins, Philadelphia

16.

Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, Pignatari AC, Tufik S (2007) Rapid detection and identification of Metallo-β- lactamase- encoding genes by multiplex real time PCR assay and melt curve analysis. J Clin Microbiol 45(2):544–547CrossRef

17.

Shi H, Trinh Q, Xu W, Zhai B, Luo Y, Huang K (2012) A universal primer multiplex PCR method for typing of toxinogenic Pseudomonas aeruginosa. Appl Microbiol Biotechnol 95:1579–1587CrossRef

18.

Assefa S, Keane TM, Otto TD, Newbold C, Berriman M (2009) ABACAS: algorithm-based automatic contiguation of assembled sequences. Bioinformatics 25:1968–1969CrossRef

19.

Seemann T (2014) Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069CrossRef

20.

Wang L, Wang Y, Fan X, Tang W, Hu J (2015) Prevalence of resistant gram-negative bacilli in bloodstream infection in febrile neutropenia patients undergoing hematopoietic stem cell transplantation: a single center retrospective cohort study. Medicine 94(45):e1931CrossRef

21.

Chaves L, Tomich LM, Salomão M, Leite GC, Ramos J, Martins RR, Rizek C, Neves P, Batista MV, Amigo U, Guimaraes T, Levin AS, Costa SF (2017) High mortality of bloodstream infection outbreak caused by carbapenem-resistant P. aeruginosa producing SPM-1 in a bone marrow transplant unit. J Med Microbiol 66:1722–9CrossRef

22.

Heidenreich D, Kreil S, Nolte F, Hofmann WK, Miethke T, Klein SA (2017) Multidrug-resistant organisms in allogeneic hematopoietic cell transplantation. Hematology 98(5):485–492

23.

Mellouli A, Chebbi Y, El Fatmi R, Raddaoui A, Lakhal A, Torjmane L, Ben Abdeljelil N, Belloumi D, Ladeb S, Ben Othmen T, Achour W (2021) Multidrug resistant bacteremia in hematopoietic stem cell transplant recipients. Tunis Med 99(2):269–276PubMed

24.

Hu Y, Li L, Li W, Xu H, He P, Yan X, Dai H (2013) Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents 42:492–496CrossRef

25.

He W, Kaniga K, Lynch AS, Flamm RK, Davies TA (2012) In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. Diagn Microbiol Infect Dis 74:417–419CrossRef

26.

Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ (2019) Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 63(8):e00779-19CrossRef

27.

Pereira SG, Rosa AC, Cardoso O (2015) Virulence factors as predictive tools for drug resistance in Pseudomonas aeruginosa. Virulence 6(5):1–4

28.

Gómez-Zorrilla S, Juan C, Cabot G, Camoez M, Tubau F, Oliver A, Dominguez MA, Ariza J, Peña C (2016) Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. Int J Antimicrob Agents 47(5):368–374CrossRef

29.

Silva FM, Carmo MS, Silbert S, Gales AC (2011) SPM-1-Producing Pseudomonas aeruginosa: analysis of the ancestor relationship using multilocus sequence typing, pulsed-field gel electrophoresis, and automated ribotyping. Microbiol Drug Resist 17(2):215–220CrossRef

30.

Hopkins KL, Meunier D, Findlay J, Mustafa N, Parsons H, Pike R, Wright L, Woodford N (2016) SPM-1 metallo-β-lactamase-producing Pseudomonas aeruginosa ST277 in the UK. J Med Microbiol 65(7):696–697CrossRef

31.

Estepa V, Rojo-Bezares B, Azcona-Gutiérrez JM, Olarte I, Torres C, Sáenz Y (2017) Caracterización de mecanismos de resistencia a carbapenémicos en aislados clínicos de Pseudomonas aeruginosa en un hospital español. Enferm Infecc Microbiol Clin 35:141–147CrossRef

32.

Silveira MC, Albano RM, Asensi MD, Carvalho-Assef AP (2016) Description of genomic islands associated to the multidrug-resistant Pseudomonas aeruginosa clone ST277. Infect Genet Evol 42:60–65CrossRef

Title: Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro
Authors: Jessica Fernandes Ramos
Gleice Leite
Roberta Cristina Ruedas Martins
Camila Rizek
Sabri Saeed Al Sanabani
Flavia Rossi
Thais Guimarães
Anna Sara Levin
Vanderson Rocha
Silvia Figueiredo Costa
Publication date: 01-02-2022
Publisher: Springer Berlin Heidelberg
Keywords: Stem Cell Transplantion
Amikacin
Meropenem
Carbapenem Antibiotic
Stem Cell Transplantation
Stem Cell Transplantation
Polymerase Chain Reaction
Pseudomonas Aeruginosa
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2022
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-021-04361-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical outcome from hematopoietic cell transplant patients with bloodstream infection caused by carbapenem-resistant P. aeruginosa and the impact of antimicrobial combination in vitro

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Detection of in-frame mutation by IS30-family insertion sequence in the phospholipid phosphatidylglycerol synthase gene (pgsA2) of high-level daptomycin-resistant Corynebacterium striatum

The association of HLA-G polymorphism with oral and genital HPV infection in men

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020

Analysis of the diagnostic accuracy of rapid antigenic tests for detection of SARS-CoV-2 in hospital outbreak situation

Blood culture time to positivity in non-β-hemolytic streptococcal bacteremia as a predictor of infective endocarditis—a retrospective cohort study

Impact of multiplexed respiratory viral panels on infection control measures and antimicrobial stewardship: a review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page